Strides Arcolab receives USFDA approval for Acetazolamide Injection

10 May 2012 Evaluate

Strides Arcolab (Strides) has received ANDA approval from USFDA for Acetazolamide Injection USP, 500 mg/ vial (preservative free) in lyophilized format. The product is expected to be launched shortly. According to IMS, the 2011 US market for Injectable Acetazolamide approximates to $10 million with only one active player.

Acetazolamide is the fourteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent.

Acetazolamide is used for adjunctive treatment of - edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

943.35 -5.80 (-0.61%)
01-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1517.90
Dr. Reddys Lab 6362.00
Cipla 1478.90
Zydus Lifesciences 1066.95
Lupin 1614.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.